Cargando…
MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults
OBJECTIVE: Growth hormone (GH) replacement therapy currently requires daily injections, which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth hormone (MOD-4023) is being developed as a once-weekly dosing regimen in patients with GH deficiency (GHD). This study’s objec...
Autores principales: | Strasburger, Christian J, Vanuga, Peter, Payer, Juraj, Pfeifer, Marija, Popovic, Vera, Bajnok, László, Góth, Miklós, Olšovská, Veˇra, Trejbalová, L‘udmila, Vadasz, Janos, Fima, Eyal, Koren, Ronit, Amitzi, Leanne, Bidlingmaier, Martin, Hershkovitz, Oren, Hart, Gili, Biller, Beverly M K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292974/ https://www.ncbi.nlm.nih.gov/pubmed/27932411 http://dx.doi.org/10.1530/EJE-16-0748 |
Ejemplares similares
-
Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
por: Bidlingmaier, Martin, et al.
Publicado: (2022) -
Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
por: Bidlingmaier, Martin, et al.
Publicado: (2023) -
Growth Hormone Research Society perspective on the development of
long-acting growth hormone preparations
por: Christiansen, Jens Sandahl, et al.
Publicado: (2016) -
Growth hormone in the tumor microenvironment
por: Chesnokova, Vera, et al.
Publicado: (2019) -
Motivation for and adherence to growth hormone replacement therapy in adults with hypopituitarism: the patients‘ perspective
por: Kreitschmann-Andermahr, Ilonka, et al.
Publicado: (2020)